165 related articles for article (PubMed ID: 27749622)
1. Plerixafor mobilization of peripheral blood hematopoietic progenitors to support further high-dose chemotherapy cycles in a patient with germ-cell tumor relapsing after previous tandem high-dose chemotherapy and hematopoietic cell transplantation: report of a case.
Miltiadous C; Dimitriadis GK; Roditis P; Kosmas C
Anticancer Drugs; 2017 Feb; 28(2):237-241. PubMed ID: 27749622
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors: a single-center experience.
Kosmas C; Athanasopoulos A; Dimitriadis G; Miltiadous C; Zilakos M; Lydakis D; Magiorkinis E; Gekas C; Daladimos T; Mylonakis N; Ziras N
Anticancer Drugs; 2014 Aug; 25(7):841-7. PubMed ID: 24625457
[TBL] [Abstract][Full Text] [Related]
3. Myeloablative chemotherapy and autologous stem cell transplantation can lead to successful postengraftment mobilization of hematopoietic progenitors to support planned subsequent cycle(s) of high-dose chemotherapy and autografting in a patient with relapsed germ-cell tumor.
Fergadis E; Gavrielatou N; Skouteris N; Athanasopoulos A; Lianos E; Kosmas C
Anticancer Drugs; 2019 Feb; 30(2):205-208. PubMed ID: 30489289
[TBL] [Abstract][Full Text] [Related]
4. Plerixafor-aided Mobilization of Peripheral Blood Hematopoietic Stem Cells to Support Subsequent High-dose Chemotherapy After a Prior Autologous Transplant.
Fergadis E; Assi A; Kranidioti E; Kosma A; Karakosta M; Miltiadous C; Dimitriadis GK; Grivas A; Athanasopoulos A; Lianos E; Kosmas C
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e50-e57. PubMed ID: 31884151
[TBL] [Abstract][Full Text] [Related]
5. Plerixafor and autologous stem cell transplantation: impressive result in a chemoresistant testicular cancer patient treated with high-dose chemotherapy.
De Blasio A; Rossi L; Zappone E; Ortu La Barbera E; Salvatori R; Pacilli M; Carbone A; Zaccarelli E; Papa A; Tomao S
Anticancer Drugs; 2013 Jul; 24(6):653-7. PubMed ID: 23698254
[TBL] [Abstract][Full Text] [Related]
6. Experience with plerixafor for hematopoietic cell mobilization in nine patients with germ cell tumors.
Daphne O'Hara VJ; Karr AH; Srivastava S; Kiel PJ
Pharmacotherapy; 2014 Jan; 34(1):85-8. PubMed ID: 23864559
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
Nieto Y; Tu SM; Bassett R; Jones RB; Gulbis AM; Tannir N; Kingham A; Ledesma C; Margolin K; Holmberg L; Champlin R; Pagliaro L
Ann Oncol; 2015 Oct; 26(10):2125-32. PubMed ID: 26199392
[TBL] [Abstract][Full Text] [Related]
8. Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor.
Goker H; Etgul S; Buyukasik Y
Transfus Apher Sci; 2015 Aug; 53(1):23-9. PubMed ID: 26099666
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of hematopoietic stem cell remobilization with plerixafor+G-CSF in adult patients with germ cell tumors.
Horwitz ME; Long G; Holman P; Libby E; Calandra GC; Schriber JR
Bone Marrow Transplant; 2012 Oct; 47(10):1283-6. PubMed ID: 22343676
[TBL] [Abstract][Full Text] [Related]
10. Feasibility study of IL-11 and granulocyte colony-stimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients.
Goldman SC; Bracho F; Davenport V; Slack R; Areman E; Shen V; Lenarsky C; Weinthal J; Hughes R; Cairo MS
J Pediatr Hematol Oncol; 2001; 23(5):300-5. PubMed ID: 11464987
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma.
Dhakal B; Veltri LW; Fenske TS; Eastwood D; Craig MD; Cumpston A; Shillingburg A; Esselman J; Watkins K; Pasquini MC; D'Souza A; Hari P; Kanate AS; Hamadani M
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1773-1780. PubMed ID: 27345140
[TBL] [Abstract][Full Text] [Related]
12. Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients.
Kobold S; Isernhagen J; Hübel K; Kilic N; Bogner C; Frickhofen N; Bokemeyer C; Fiedler W
Bone Marrow Transplant; 2011 Aug; 46(8):1053-6. PubMed ID: 21102500
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy with haematopoietic stem-cell support in patients with poor prognosis, relapsed or refractory germ cell tumours.
El-Helw LM; Naik JD; Chester JD; Joffe JK; Selby PJ; Coleman RE
BJU Int; 2006 Sep; 98(3):519-25. PubMed ID: 16925746
[TBL] [Abstract][Full Text] [Related]
14. Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide.
Yoshifuji K; Toya T; Adachi H; Fujita M; Wada A; Konuma R; Kishida Y; Konishi T; Nagata A; Yamada Y; Kaito S; Kumagai T; Inamoto K; Akiyama M; Igarashi A; Najima Y; Doki N; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
Int J Hematol; 2019 Jul; 110(1):115-118. PubMed ID: 30989487
[TBL] [Abstract][Full Text] [Related]
15. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
16. Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.
Worel N; Fritsch G; Agis H; Böhm A; Engelich G; Leitner GC; Geissler K; Gleixner K; Kalhs P; Buxhofer-Ausch V; Keil F; Kopetzky G; Mayr V; Rabitsch W; Reisner R; Rosskopf K; Ruckser R; Zoghlami C; Zojer N; Greinix HT
J Clin Apher; 2017 Aug; 32(4):224-234. PubMed ID: 27578390
[TBL] [Abstract][Full Text] [Related]
17. Successful stem-cell mobilization and transplantation using plerixafor in a patient with a germ cell tumor.
Tuffaha H; Abdel-Rahman FA
Hematol Oncol Stem Cell Ther; 2010; 3(4):203-5. PubMed ID: 21150242
[TBL] [Abstract][Full Text] [Related]
18. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
19. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
Flomenberg N; Comenzo RL; Badel K; Calandra G
Biol Blood Marrow Transplant; 2010 May; 16(5):695-700. PubMed ID: 20067838
[TBL] [Abstract][Full Text] [Related]
20. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor.
Abhyankar S; DeJarnette S; Aljitawi O; Ganguly S; Merkel D; McGuirk J
Bone Marrow Transplant; 2012 Apr; 47(4):483-7. PubMed ID: 21725372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
